ASH 2016 | New targets for hematological malignancy therapies

Olaf Heindenreich

Olaf Heidenreich, PhD from Newcastle University, Newcastle, UK discusses what he finds most exciting about the new treatments in cancer and hematology. He talks about the neglected connection between epigenetics and genomics, to the classical biochemistry of metabolism. This renewed focus on ‘old-fashioned’ biochemistry brings up a plethora of new and exciting targets for cancer therapy and hematology. Recorded at the 2016 American Society of Hematology (ASH) Annual Meeting, held in San Diego, CA.

Share this video  
1st December 2016